Turning Point Therapeutics Inc. has the chance to secure a piece of the market for ROS1-positive non-small cell lung cancer with its ROS1/TRK inhibitor, repotrectinib, after presenting positive Phase I/II data that showed efficacy in line with competitors, but with longer durability.
The company announced topline data by blinded independent central review (BICR) from the TRIDENT-1 trial. The data showed confirmed overall response rates (ORR) in both tyrosine kinase inhibitor (TKI)-naïve and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?